Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published on August 13
When executives buy shares after bad news, they're betting their own money on recovery. This insider confidence often signals opportunities that the broader market has missed.
The global obesity treatment market is exploding, with GLP-1 drugs already generating tens of billions in revenue and still in early adoption phases worldwide.
Beyond established players, numerous companies are developing next-generation therapies, novel delivery methods, and breakthrough approaches that could reshape this entire sector.
When company executives buy shares after a stock drop, it often signals deep confidence in their business. Following Eli Lilly's clinical trial setback, top executives including the CEO invested millions in company shares, suggesting they believe the market overreacted to short-term news whilst the long-term GLP-1 opportunity remains strong.
This group focuses on the rapidly expanding obesity treatment sector, dominated by GLP-1 drugs but also including next-generation therapies and novel delivery systems. The market is highly competitive and can be volatile, but represents one of healthcare's fastest-growing segments with enormous potential as obesity rates continue rising globally.
These companies were handpicked to capture the full spectrum of the weight-loss drug market. From established leaders like Eli Lilly and Novo Nordisk to innovative challengers developing breakthrough therapies, this collection provides exposure to both proven players and emerging opportunities in this dynamic healthcare segment.
Market capitalisation breakdown for the provided GLP-1-focused executive conviction basket.
LLY: $756.76B
NVO: $180.85B
ALT: $356.56M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Current Price
$1,279.99
Eli Lilly leads the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, generating billions in revenue despite recent clinical trial setba...
Eli Lilly leads the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, generating billions in revenue despite recent clinical trial setbacks.
NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1
NVO
Current Price
$46.67
Novo Nordisk pioneered the GLP-1 space with Ozempic and Wegovy, maintaining a strong competitive position in the rapidly growing obesity treatment mar...
Novo Nordisk pioneered the GLP-1 space with Ozempic and Wegovy, maintaining a strong competitive position in the rapidly growing obesity treatment market.
ALTIMMUNE INC
ALT
Current Price
$3.20
Altimmune develops next-generation obesity treatments including pemvidutide, positioning itself as a potential challenger in the competitive GLP-1 lan...
Altimmune develops next-generation obesity treatments including pemvidutide, positioning itself as a potential challenger in the competitive GLP-1 landscape.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 421.3% over the next year.
11 of 12 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+421.30%
